Uncertainty in the treatment of anemia in chronic kidney disease

Reviews in Cardiovascular Medicine

Volumn 6, Issue SUPPL. 3, 2005, Pages

  Pfeffer, Marc A ^a   Solomon, Scott D ^a   Ivanovich, Peter ^b   Singh, Ajay K ^a   McMurray, John J V ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c WESTERN INFIRMARY   (United Kingdom)

Author keywords

Anemia; Chronic kidney disease; Erythropoietin; Randomized controlled clinical trials

Indexed keywords

FLOSEQUINAN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG INFORMATION; HEART FAILURE; HEART HEMODYNAMICS; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; INTERMETHOD COMPARISON; METHODOLOGY; MORBIDITY; MORTALITY; PATIENT CARE; PRACTICE GUIDELINE; PROGNOSIS; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION;

ANEMIA; HUMANS; KIDNEY FAILURE, CHRONIC; RANDOMIZED CONTROLLED TRIALS;

EID: 28644443756     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Devereaux PJ, Yusuf S. The evolution of the randomized controlled trial and its role in evidence-based decision making. J Intern Med. 2003;254:105-113.
2. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med. 1996;125:605-613.
3. Ioannidis JP. Contradicted and initially stronger effects in highly cited clinical research. JAMA. 2005;294:218-228.
4. Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis. 1995;38:199-210.
5. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288: 321-333.
6. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324:781-788.
7. Packer M, Narahara KA, Elkayam U, et al. Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study. J Am Coll Cardiol. 1993;22:65-72.
8. Massie BM, Berk MR, Brozena SC, et al. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET). Circulation. 1993;88:492-501.
9. FDA Drug and Biologic Approvals-1992. www.fda.gov/bbs/topics/ANSWERS/ANS00463.html.
10. van Veldhuisen DJ, Poole-Wilson, PA. The underreporting of results and possible mechanisms of "negative" drug trials in patients with chronic heart failure. Inter J Cardiol. 2001;80:19-27.
11. Cohn JN, Goldstein SO, Greenberg BH, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med. 1998;339:1810-1816.
12. Smith GC, Pell JP. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. BMJ 2003;327:1459-1461.
13. Califf RM, Peterson ED, Gibbons RJ, et al. Integrating quality into the cycle of therapeutic development. J Am Coll Cardiol. 2002;40:1895-1901.
14. Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164:659-663.
15. Abramson JL, Jurkovitz CT, Vaccarino V, et al. Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study. Kidney Int. 2003;64:610-615.
16. McCullough PA, Lepor NE. Piecing together the evidence on anemia: the link between chronic kidney disease and cardiovascular disease. Rev Cardiovasc Med. 2005;6:S4-S12.
17. Weiner DE, Tighiouart H, Vlagopoulos PT, et al. Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol. 2005; 16:1803-1810.
18. Cody J, Daly C, Campbell M, et al. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database Syst Rev. 2005:CD003266.
19. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med. 1987;317:141-145.
20. Sackett DL. Equipoise, a term whose time (if it ever came) has surely gone. CMAJ. 2000;163: 835-836.
21. Anand I. Pathogenesis of anemia in cardiorenal disease. Rev Cardiovasc Med. 2005;6:S13-S21.
22. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int. 2004;66:753-760.
23. Heeschen C, Aicher A, Lehmann R, et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood. 2003;102:1340-1346.
24. Goldschmidt-Clermont P, Diehl A. Arterial homeostasis, inflammation, and erythropoietic growth factors. Rev Cardiovasc Med. 2005;6: S22-S26.
25. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584-590.
26. Leyland-Jones B, BEST Investigators. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncology. 2003;5:206-207.
27. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003;362:125S-1260.
28. Mix TC, Brenner RM, Cooper ME, et al. Rationale - Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J. 2005;149:408-413.
29. Macdougall IC. CREATE: new strategies for early anaemia management in renal insufficiency. Nephrol Dial Transplant. 2003;18(Suppl 2): ii13-16.
30. Singh AK, Bhaduri S, Day B, et al. The CHOIR study: Health related quality of life (HRQOL) in patients with anemia of chronic kidney disease. JASN. 2003;14:456a.
31. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582-1587.
32. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-393.